Will A Dividend Keep Investors Happy As Amgen Waits For Its Pipeline To Pan Out?
This article was originally published in The Pink Sheet Daily
Executive Summary
Amgen outlines its strategic priorities through 2016, but analysts and investors seem more concerned with near-term initiatives that could pan out before year's end.
You may also be interested in...
Amgen’s Stealth Enbrel Patent May Block Biosimilars; Scenario May Apply To Other Biologics
Amgen’s patent may keep Enbrel biosimilars off the market until at least 2028. Other biosimilar sponsors could face similar submarine patents that derail their commercialization plans.
Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn
The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.
Amid A Flurry Of EU Positive Opinions Benlysta And Yervoy Shine, While Fampyra Is Reborn
The European Medicines Agency has recommended an impressive number of drugs for approval, including Merck & Co's hepatitis C therapy, Victrelis, Theravance's Vibativ and Amgen's Xgeva.